UBS raised the firm’s price target on 10x Genomics (TXG) to $14 from $13 and keeps a Neutral rating on the shares. While 10x Genomics posted a quarterly beat and guidance above expectations, the muted demand environment is persisting, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target raised to $15 from $13 at JPMorgan
- 10x Genomics price target raised to $19 from $16 at Canaccord
- Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks
- 10x Genomics price target raised to $17 from $15 at Barclays
- 10x Genomics: Hold Rating Amid Resilience and Challenges in U.S. Academic and Government Sectors